Mizuho raises CVS Health's PT on its business diversification

Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with "outperform" rating

New PT represents ~14% upside to the stock's close

Brokerage says CVS is "an attractive investment opportunity given the diversification of its business"

"We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model" - brokerage adds

Eighteen of 29 brokerages rate the stock "buy" or higher, eleven "hold"; their median PT is $70.89 - data compiled by LSEG

CVS has fallen 12.4% in the past 12 months